Results 1 to 10 of about 40,685 (224)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
Медицинский совет, 2021 Dyslipidemia makes a substantial contribution to the mortality as one of the leading pathogenetic factors for cardiovascular diseases. The nature and degree of the effect on the blood lipid spectrum may vary in the lipid-lowering drugs from different ...
A. A. Shikaleva +2 more
doaj +3 more sources
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis [PDF]
Lipids in Health and Disease, 2021 Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis.
Susanne Feder +7 more
doaj +2 more sources
PCSK9 induces a pro-inflammatory response in macrophages [PDF]
, 2018 Intraplaque release of inflammatory cytokines from macrophages is implicated in atherogenesis by inducing the proliferation and migration of media smooth muscle cells (SMCs). PCSK9 is present and released by SMCs within the atherosclerotic plaque but its
Adorni, Maria Pia +12 more
core +5 more sources
PCSK9 Gene Polymorphisms Associated With the Risk of Myocardial Infarction in Iranian Patients [PDF]
International Journal of Basic Science in Medicine, 2021 Introduction: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulatory protein in lipid metabolism and a candidate gene in the etiology of cardiovascular diseases.
Farshad Namordizadeh, Mahboobeh Nasiri
doaj +1 more source
PCSK9 is not secreted from mature differentiated intestinal cells
Journal of Lipid Research, 2021 Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes lysosomal degradation of the LDL receptor and is a key regulator of cholesterol metabolism. After the liver, the small intestine is the second organ that highly expresses PCSK9.
Moreau François +17 more
doaj +1 more source
Vaccines, 2022 Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation ...
Louise Goksøyr +8 more
doaj +1 more source
Journal of Lipid Research, 2022 Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) regulates the cell-surface localization of LDL receptors in hepatocytes and is associated with LDL and lipoprotein(a) [Lp(a)] uptake, reducing blood concentrations.
Ioannis Dafnis +5 more
doaj +1 more source
Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function. [PDF]
PLoS ONE, 2015 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a soluble protein that directs membrane-bound receptors to lysosomes for degradation. In the most studied example of this, PCSK9 binding leads to the degradation of low density lipoprotein receptor
Rachel M DeVay +3 more
doaj +1 more source
Archives of Medical Science, 2021 Introduction The aim of the study was to study a nanoliposomal anti-PCSK9 vaccine as a novel approach for cholesterol lowering via PCSK9 inhibition. Material and methods An immunogenic peptide construct termed immunogenic fused PCSK9-tetanus (IFPT) was ...
Amir Abbas Momtazi-Borojeni +4 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 The effect of high physical activity, performed as voluntary running wheel exercise, on inflammation and vascular adaptation may differ between normotensive and spontaneously hypertensive rats (SHRs). We investigated the effects of running wheel activity
Rolf Schreckenberg +4 more
doaj +1 more source